Page 19 - Guideline

09010:Layout 1 3/18/10 9:26 PM Page E37

Management of testicular germ cell cancer

137. Hendry WF, A’Hern RP, Hetherington JW, et al. Paraaortic lymphadenectomy after chemotherapy for 162. Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for dissemi-
metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol nated nonseminomatous germ cell tumour s: prognostic factors and role of postsurgery chemothera-
1993;71:208-13. py—results from an international study group. J Clin Oncol 2001;19:2647-57.
138. Aprikian AG, Herr HW, Bajorin DF, et al. Resection of postchemotherapy residual masses and limited 163. Azar JM, Schneider BP, Einhorn LH. Is the blood-brain barrier relevant in metastatic germ cell tumour ?
retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell Int J Radiat Oncol Biol Phys 2007;69:163-6.
tumour s. Cancer 1994;74:1329-34. 164. Spears WT, Morphis JG 2nd, Lester SG, et al. Brain metastases and testicular tumour s: long-term sur-
139. Wood DP Jr, Herr HW, Heller G, et al. Distribution of retroperitoneal metastases after chemotherapy in vival. Int J Radiat Oncol Biol Phys 1992;22:17-22.
patients with nonseminomatous germ cell tumour s. J Urol 1992;148:1812-5; discussion 1815-6. 165. Bokemeyer C, Nowak P, Haupt A, et al. Treatment of brain metastases in patients with testicular can-
140. Rabbani F, Goldenberg SL, Gleave ME, et al. Retroperitoneal lymphadenectomy for post-chemothera- cer. J Clin Oncol 1997;15:1449-54.
py residual masses: is a modified dissection and resection of residual masses sufficient? Br J Urol 166. Hartmann JT, Bamberg M, Albers P. Multidisciplinary treatement and prognosis of patients with central
1998;81:295-300. nervous metastases (CNS) from testicular germ cell tumour (GCT) origin. Proc Am Soc Clin Oncol
141. Beck SD, Foster RS, Bihrle R, et al. Is full bilateral retroperitoneal lymph node dissection always neces- 2003;22:400.
sary for postchemotherapy residual tumour ? Cancer 2007;110:1235-40. 167. Kollmannsberger C, Nichols C, Bamberg M, et al. First-line high-dose chemotherapy +/- radiation thera-
142. Carver BS, Shayegan B, Eggener S, et al. Incidence of metastatic nonseminomatous germ cell tumour py in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 2000;11:553-9.
outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin 168. Miller KD, Loehrer PJ, Gonin R, et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin
Oncol 2007;25:4365-9. in recurrent seminoma. J Clin Oncol 1997;15:1427-31.
143. Stenning SP, Parkinson MC, Fisher C, et al. Postchemotherapy residual masses in germ cell tumour 169. Schmoll HJ, Beyer J. Prognostic factors in metastatic germ cell tumour s. Semin Oncol 1998;25:174-85.
patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working 170. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for
Party. Cancer 1998;83:1409-19. patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18:2413-8.
144. Baniel J, Foster RS, Rowland RG, et al. Complications of post-chemotherapy retroperitoneal lymph node 171. Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage
dissection. J Urol 1995;153(3 Pt 2):976-80. therapy in recurrent germ cell tumour . J Clin Oncol 1998;16:2500-4.
145. Rassweiler JJ, Frede T, Lenz E, et al. Long-term experience with laparoscopic retroperitoneal lymph 172. Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B com-
node dissection in the management of low-stage testis cancer. Eur Urol 2000;37:251-60. pared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumour :
146. Janetschek G, Peschel R, Hobisch A, et al. Laparoscopic retroperitoneal lymph node dissection. J Endourol a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer
2001;15:449-53; discussion 453-5. study. J Clin Oncol 1998;16:692-701.
147. Steiner H, Peschel R, Janetschek G, et al. Long-term results of laparoscopic retroperitoneal lymph node 173. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an
dissection: a single-center 10-year experience. Urology 2004;63:550-5. effective second-line therapy for patients with relapsed testicular germ cell tumour s. J Clin Oncol
148. Hartmann JT, Candelaria M, Kuczyk MA, et al. Comparison of histological results from the resection of 2005;23:6549-55.
residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. 174. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treat-
Eur J Cancer 1997;33:843-7. ment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol
149. Steyerberg EW, Donohue JP, Gerl A, et al. Residual masses after chemotherapy for metastatic testicular 2005;16:1152-9.
cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re- 175. Motzer RJ, Cooper K, Geller NL, et al. The role of ifosfamide plus cisplatin-based chemotherapy as sal-
analysis of Histology in Testicular Cancer (ReHiT) Study Group. J Urol 1997;158:474-8. vage therapy for patients with refractory germ cell tumour s. Cancer 1990;66:2476-81.
150. Tognoni PG, Foster RS, McGraw P, et al. Combined post-chemotherapy retroperitoneal lymph node dis- 176. Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cis-
section and resection of chest tumour under the same anesthetic is appropriate based on morbidity and platin plus either vinblastine or etoposide. Ann Intern Med 1988;109:540-6.
tumour pathology. J Urol 1998;159:1833-5. 177. Droz JP, Ribrag V, Ghosn M, et al. Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose
151. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Thoracotomy for postchemotherapy resection of pulmonary cisplatin (VIhP regimen) in refractory germ cell tumour s. Prog Clin Biol Res 1989;303:739-47.
residual tumour mass in patients with nonseminomatous testicular germ cell tumour s: aggressive sur- 178. Mardiak J, Salek T, Sycova-Mila Z, et al. Paclitaxel plus ifosfamide and cisplatin in second-line treat-
gical resection is justified. Chest 1997;112:967-73. ment of germ cell tumour s: a phase II study. Neoplasma 2005;52:497-501.
152. Brenner PC, Herr HW, Morse MJ, et al. Simultaneous retroperitoneal, thoracic, and cervical resection of 179. Mead GM, Cullen MH, Huddart R, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin)
postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumour s of given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a
the testis. J Clin Oncol 1996;14:1765-9. medical research council trial. Br J Cancer 2005;93:178-84.
153. De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron 180. Beyer J, Stenning S, Gerl A, et al. High-dose versus conventional-dose chemotherapy as first-salvage
emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin treatment in patients with non-seminomatous germ-cell tumour s: a matched-pair analysis. Ann Oncol
Oncol 2001;19:3740-4. 2002;13:599-605.
154. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomogra- 181. Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carbo-
phy is a reliable predictor for viable tumour in postchemotherapy seminoma: an update of the prospec- platin, and etoposide salvage therapy for germ cell tumour patients. J Clin Oncol 2000;18:1173-80.
tive multicentric SEMPET trial. J Clin Oncol 2004;22:1034-9. 182. Vaena DA, Abonour R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ
155. Albers P, Weissbach L, Krege S, et al. Prediction of necrosis after chemotherapy of advanced germ cell cell malignancies with adverse prognostic variables. J Clin Oncol 2003;21:4100-4.
tumour s: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 183. Lorch A, Kollmannsberger C, Hartmann JT, et al. Single versus sequential high-dose chemotherapy in
2004;171:1835-8. patients with relapsed or refractory germ cell tumour s: a prospective randomized multicenter trial of
156. Herr HW, Sheinfeld J, Puc HS, et al. Surgery for a post-chemotherapy residual mass in seminoma. J the German Testicular Cancer Study Group. J Clin Oncol 2007;25:2778-84.
Urol 1997;157:860-2. 184. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metasta-
157. Ravi R, Ong J, Oliver RT, et al. The management of residual masses after chemotherapy in metastatic tic germ-cell tumour s. N Engl J Med 2007;357:340-8.
seminoma. BJU Int 1999;83:649-53. 185. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxali-
158. Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results platin in patients with intensively pretreated or refractory germ cell cancer: a study of the German
and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996;14:454-60. Testicular Cancer Study Group. J Clin Oncol 2004;22:108-14.
159. Hofmockel G, Gruss A, Theiss M. Chemotherapy in advanced seminoma and the role of postcytostatic 186. Hartmann JT, Schmoll HJ, Kuczyk MA, et al. Postchemotherapy resections of residual masses from
retroperitoneal lymph node dissection. Urol Int 1996;57:38-42. metastatic non-seminomatous testicular germ cell tumour s. Ann Oncol 1997;8:531-8.
160. Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic semino- 187. Oldenburg J, Martin JM, Fossa SD. Late relapses of germ cell malignancies: incidence, management,
ma—a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997;33:829-35. and prognosis. J Clin Oncol 2006;24:5503-11.
161. Mosharafa AA, Foster RS, Leibovitch BC. Is the postchemotherapy resection of seminomatous elements 188. Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170-6.
associated with higher acute morbidity? J Urol 2002;167:172. 189. Gerl A, Clemm C, Schmeller N, et al. Late relapse of germ cell tumour s after cisplatin-based chemother-
apy. Ann Oncol 1997;8:41-7.

CUAJ • April 2010 • Volume 4, Issue 2 E37